Division of GlaxoSmithKline PLC
Latest From Tesaro Inc.
The Coronavirus outbreak makes its first dent into pharma's 2020 prospects as AstraZeneca admits possible impact, while could AbbVie's aesthetic plans raise the prospect of another GSK-style spin off?
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
- Specialty Pharmaceuticals
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Lonnie Moulder, CEO
Timothy Pearson, EVP, CFO
Mary Lynne Hedley, PhD, Pres. & COO
Grant C Bogle, SVP, Chief Commercial Officer
William Aitchison, PhD, SVP, Technical ops
Allene Diaz, SVP, Global Commercial Development
Joseph Farmer, SVP, General Counsel & Corp Secretary
Martin Huber, MD, SVP, CMO
Jennifer Jackson, PhD, SVP, Global RA and QA
Orlando Oliveira, SVP, International
- Contact Info
Phone: (339) 970-0900
1000 Winter St.
Waltham, MA 02451
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.